Overall safety of the octreotide implant and octreotide lar were similar.
奥曲肽植入物的整体安全性与奥曲肽类似物相似。
Randomization was in a 3:1 ratio to either 6-month octreotide implant or monthly octreotide LAR injections.
按3：1比例随机分到6个月奥曲肽植入或每月奥曲肽类似物注射。
Diarrhea and headache were more frequent with the implant, while cholecystitis and hypertension were more frequent with octreotide LAR.
奥曲肽植入物常见的不良反应为腹泻和头痛，而奥曲肽类似物更常见的为胆囊炎和高血压。
应用推荐